News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Agenus (Formerly known as Antigenics Inc. - Lexington, MA) (AGEN) and VaxLogic, LLC Execute QS-21 Stimulon Adjuvant Licensing Agreement for Addiction, Allergy and Respiratory Vaccines


9/26/2013 10:11:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN) today announced that it is has entered into a non-exclusive license agreement with VaxLogic, LLC, a subsidiary of PharmLogic LLC, for the use of QS-21 Stimulon®1 adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES